Celldex Therapeutics, Inc. (CLDX) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Celldex Therapeutics, Inc. (CLDX) stock forecast summary
Our AI scores Celldex Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Celldex Therapeutics, Inc. is a mid-cap company with a market capitalization of $2.35B. It ranks number 4 by market capitalization among the 17 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its Net Margin of 25127.0% is the highest of the 11 peers that report one.
For CLDX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 14.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 21.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CLDX included.
CLDX price chart and AI forecast
How CLDX ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Celldex Therapeutics, Inc. (CLDX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | CLDX | Rank |
|---|---|---|
| Market Cap | $2.35B | 4/17 |
| P/B Ratio | 3.61x | 4/12 |
| EPS | $-5.11 | – |
| Book Value/Share | $8.27 | – |
| Revenue/Share | $-0.02 | – |
| FCF/Share | $-3.31 | – |
Profitability & Margins
| Metric | CLDX | Rank |
|---|---|---|
| ROE | -47.6% | 7/10 |
| ROA | -42.8% | 7/12 |
| ROIC | -50.6% | 8/12 |
| Operating Margin | 27192.1% | 1/14 |
| Net Margin | 25127.0% | 1/11 |
| EBT Margin | 24866.1% | 1/14 |
Financial Health
| Metric | CLDX | Rank |
|---|---|---|
| Current Ratio | 10.97x | 2/16 |
| D/E Ratio | 0.11x | 11/12 |
| Financial Leverage | 1.11x | 11/12 |
| Interest Coverage | -260.2x | 12/15 |
| Working Capital | $603M | 2/16 |
Cash Flow
| Metric | CLDX | Rank |
|---|---|---|
| Operating Cash Flow | -$252M | 14/16 |
| Free Cash Flow | -$260M | 8/10 |
| Capital Spending | -$8M | 7/10 |
| FCF/Sales | 21117.0% | 1/10 |
| CapEx/Sales | -631.4% | 10/10 |
Operational Efficiency
| Metric | CLDX | Rank |
|---|---|---|
| Asset Turnover | 0.00x | 11/12 |
| Fixed Assets Turnover | -0.1x | 12/12 |
Income Statement
| Metric | CLDX | Rank |
|---|---|---|
| Total Revenue | -$1M | 12/12 |
| Operating Income | -$334M | 14/15 |
| Net Income | -$309M | 10/12 |
| R&D Expense | $283M | 2/16 |
Dividend & Shareholder Information
| Metric | CLDX | Rank |
|---|---|---|
| Shares Outstanding | 79M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $664M | 92.0% of assets |
| Cash & Short-term Investments | $27M | 3.7% of assets |
| Total Liabilities | $72M | 10.0% of assets |
| Short-term Debt | $49M | 6.8% of assets |
CLDX quarterly financials and insider trading
Celldex Therapeutics, Inc. (CLDX) industry peers
Companies classified under the same SEC industry code as Celldex Therapeutics, Inc. (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CLDX Celldex Therapeutics, Inc. | $2.35B | |
| IDXX Idexx Laboratories Inc /De | $53.26B | |
| LNTH Lantheus Holdings, Inc. | $6.57B | |
| NEOG Neogen Corp | $2.57B | |
| NTLA Intellia Therapeutics, Inc. | $1.59B | |
| QDEL Quidelortho Corp | $734M | |
| ACHV Achieve Life Sciences, Inc. | $692M | |
| MYGN Myriad Genetics Inc | $566M | |
| TKNO Alpha Teknova, Inc. | $482M | |
| ICCC Immucell Corp /De/ | $90M | |
| IMDX Insight Molecular Diagnostics Inc. | $81M | |
| AWHL Aspira Women's Health Inc. | $9M | |
| BMRA Biomerica Inc | $7M | |
| CDIO Cardio Diagnostics Holdings, Inc. | $5M | |
| TRIB Trinity Biotech Plc | $5M | |
| QCLS Q/C Technologies, Inc. | $3M | |
| VNRX Volitionrx Ltd | $3M |
Where CLDX sits on the market map
Celldex Therapeutics, Inc. (CLDX) stock news
Loading...
Celldex Therapeutics, Inc. (CLDX) stock forecast FAQ
What is the Celldex Therapeutics, Inc. (CLDX) stock forecast?
Our AI scores Celldex Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Celldex Therapeutics, Inc. stock predictions?
For CLDX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 14.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 21.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Celldex Therapeutics, Inc. forecasts updated?
Celldex Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Celldex Therapeutics, Inc.'s industry peers?
17 issuers in our coverage, CLDX included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL), Achieve Life Sciences, Inc. (ACHV).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.